Shots:
Incyte has entered into a global collaboration & license agreement with Halozyme to evaluate additional SC formulations of INCA033989 for pts with mutCALR-expressing myeloproliferative neoplasms, using Halozyme's Enhanze tech
As per the deal, Halozyme will receive an upfront payment, as well as milestone payments, plus royalties, with Incyte having an option to nominate up…
